<DOC>
	<DOCNO>NCT02284139</DOCNO>
	<brief_summary>The efficacy epidermal growth factor receptor ( EGFR ) inhibitor demonstrate patient non-small cell lung cancer ( NSCLC ) , pancreatic cancer ( PC ) colorectal cancer ( CRC ) . Dermatological reaction cause significant physical psycho-social discomfort patient . In present study , investigator evaluate effect epidermal growth factor ( EGF ) ointment EGFR inhibitor-related skin side effect ( ERSEs ) .</brief_summary>
	<brief_title>Pilot Trial EGF Ointment Patients With EGFR-i Related Skin Side Effects</brief_title>
	<detailed_description>The current study include patient diagnose advanced NSCLC PC CRC , pathological confirmation . The inclusion criterion NSCLC treat erlotinib alone PC treat gemcitabine erlotinib combination chemotherapy CRC treat cetuximab and5-Fluorouracil ( 5-FU ) +Irinotecan+leucovorin ( LV ) ( FOLFIRI ) , 5-FU+Oxaliplatin+LV ( FOLFOX ) sufficient liver , kidney , bone marrow function undergo treatment . All patient Grade ≥2 ERSEs accord National Cancer Institute 's Common Terminology Criteria Adverse Events ( NCI-CTCAE ) v. 4.03 . The patient randomize 3 group ; Placebo group , Arm 1 , Arm 2 . Arm 1 treat 1ppm concentration EGF ointment . Arm 2 treat 20ppm concentration EGF ointment . And placebo group treat 0ppm concentration EGF ointment .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>1 . Age : old 20 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 3 . Histologically confirm lung cancer , pancreatic cancer , colon cancer 4 . Patients take EGFR inhibitor follow reason EGFR mutation ( + ) NSCLC adenocarcinoma 1st line treatment NSCLC ≥ 2nd line treatment Pancreatic cancer adenocarcinoma 1st line treatment Gemcitabine Colon cancer adenocarcinoma 1st line treatment Irinotecan ( FOLFIRI ) 5 . Patients EGFR inhibitor relate skin side effect ( ERSE ) Gr≥2 ( NCICTC V4.0 ) 6 . A patient willingness comply study protocol study period capable comply 7 . A patient sign informed consent prior participation study understand he/she right withdrawal participation study time without disadvantage 1 . A patient previous active passive immunotherapy 2 . A pregnant lactating patient 3 . A patient childbearing potential without tested pregnancy baseline positive . ( A postmenopausal woman amenorrhea period least 12 month longer consider nonchildbearing potential . ) 4 . A patient history uncontrolled seizure , central nervous system disorder psychiatric disorder consider clinically significant investigator would prohibit understanding informed consent may consider interfere compliance administration study medication 5 . A patient history dermatologic care ( except transient urticaria ) within 4 week 6 . A patient clinically significant ( i.e . active ) heart disease ( e.g . congestive heart failure , symptomatic coronary artery disease , cardiac arrhythmia , etc ) myocardial infarction within past 12 month 7 . A patient interstitial pneumonia diffuse symptomatic fibrosis lung . 8 . Organ allogenic transplantation require immunosuppressive therapy . Any waiver inclusion exclusion criterion must approve investigator sponsor caseby case basis prior enrol subject 9 . Known allergy , hypersensitivity , intolerance study drug , chemotherapy drug use clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>EGF ointment</keyword>
	<keyword>EGFR inhibitor</keyword>
	<keyword>Skin side effect</keyword>
</DOC>